Welcome to LookChem.com Sign In|Join Free

CAS

  • or

61-33-6

Post Buying Request

61-33-6 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

61-33-6 Usage

Brand Name(s) in US

Penicillin G potassium or sodium: Many brands Penicillin G benzathine: Benza-Pen, and other names Penicillin G, Procaine: Generic Penicillin V: Pen-Vee

Description

Penicillin was the first natural antibiotic used to treat bacterial infections and continues to be one of the most important antibiotics.The name comes from the fungus genus Penicillium from which it was isolated. Penicillus is Latin for brush and refers to the brushlike appearance of filamentous Penicillium species.Species of this genus are quite common and appear as the bluish-green mold that appears on aged bread, fruit, and cheese. The term penicillin is a generic term that refers to a number of antibiotic compounds with the same basic structure. Therefore it is more appropriate to speak of penicillins than of penicillin. The general penicillin structure consists of a β-lactam ring and thiazolidine ring fused together with a peptide bonded to a variable R group. Penicillin belongs to a group of compounds called β-lactam antibiotics. This in turn inhibits the formation of peptidoglycan cross-links in bacteria cell walls.

History

The discovery of penicillin is generally credited to Alexander Fleming (1881 1955) in 1928, but the development of penicillin as an antibiotic took place sporadically over the last decades of the 19th century and first half of the 20th century. Mass production of penicillin by U.S.firms started in 1943,and it was used immediately to treat wounded soldiers. Penicillin reduced suff ering, prevented amputations,cured pneumonia,and saved thousands of lives during the war and was hailed as a miracle drug. The United States increased production throughout the war years and after the war widespread civilian use commenced. Fleming, Florey,and Chain shared the Nobel Prize in physiology or medicine in 1945 for their work on penicillin.

Uses

Different sources of media describe the Uses of 61-33-6 differently. You can refer to the following data:
1. Benzylpenicillin is the drug of choice for infections caused by sensitive organisms. This includes streptococci infections (except enterococci), gonococci, and meningococci that do not produce beta-lactam anaerobes. Benzylpenicillin is used for croupous and focal pneumonia, skin infections, soft tissue and mucous membranes, periotonitis, cystisis, syphilis, diphtheria, and other infectious diseases. Synonyms of this drug are megacillin,
2. Penicillin is an antimicrobial agent.
3. Antibacterial.

Indications

Benzylpenicillin or penicillin G has a narrow antimicrobial spectrum. It is active with respect to Gram-positive bacteria (staphylococcus, streptococcus, and pneumococci), causative agent of diphtheria, and anthrax bacillus. Gram-negative bacteria are resistant to it. Benzylpenicillin is broken down by stomach acid and destroyed by staphylococcus penicillinase.

Antimicrobial activity

It has intrinsic activity against almost all Grampositive pathogens, but is no longer effective against most staphylococci. Most species of streptococci are susceptible, including group B streptococci, an important cause of neonatal infections. Enterococci are more resistant than streptococci. Other susceptible Gram-positive organisms include non-β-lactamase-producing Bacillus anthracis and Listeria monocytogenes. The spirochetes Borrelia burgdorferi and Treponema pallidum are also susceptible. The aerobic Gram-negative cocci Neisseria gonorrhoeae and N. meningitidis were initially highly susceptible to benzylpenicillin, but β-lactamase-producing strains of gonococci are now common. H. influenzae and Moraxella catarrhalis are usually resistant due to β-lactamase production. The Enterobacteriaceae and most other aerobic Gram-negative bacilli are resistant, as a result of β-lactamase production or the impermeability of the bacterial cell wall. Other resistant organisms include mycobacteria, mycoplasmas, Nocardia spp., rickettsiae and chlamydiae. Anaerobic Gram-positive cocci are susceptible in the absence of β-lactamase production. Most clostridia strains are susceptible, but resistance can be observed. Anaerobic Gram-negative bacilli vary in their sensitivity: the Bacteroides fragilis group is resistant as the result of β-lactamase action, but many Prevotella and Fusobacterium spp. are susceptible. Benzylpenicillin exhibits concentration-dependent bactericidal activity against growing organisms. Killing of highly susceptible Gram-positive cocci seldom proceeds to eradication, with measurable numbers of survivors (‘persisters’), which are fully susceptible on retesting. Some strains of streptococci (including group B) and pneumococci show very large numbers of persisters, resulting in a large difference between the minimum inhibitory concentration (MIC) and the minimum bactericidal concentration (MBC), a phenomenon known as ‘tolerance’. Combination with aminoglycosides results in pronounced bactericidal synergy.

Acquired resistance

Staph. aureus was originally highly susceptible to benzylpenicillin, but at least 85–90% of clinical isolates are now β-lactamase-producing strains. Most clinical isolates of coagulase- negative staphylococci are also resistant. β-Lactamaseproducing strains of E. faecalis produce an enzyme identical to staphylococcal penicillinases, but these strains are increasingly uncommon. The emergence of penicillin-resistant staphylococci, enterococci and pneumococci, due to the acquisition of mosaic PBPs with decreased binding affinity for penicillin, has been described worldwide. Most strains of penicillin- resistant Gram-positive clinical isolates also demonstrate reduced susceptibility to other β-lactam agents but, in rare cases, cross-resistance is not seen for all cephalosporins. Strains of N. gonorrhoeae for which the MIC of benzylpenicillin increased from 0.06 mg/L to >2 mg/L appeared in the 1970s, as the result of the production of modified PBPs with reduced affinity for β-lactam antibiotics; fully resistant strains producing TEM-1 β-lactamase also emerged. Currently penicillin resistance occurs in more than 60% of isolates in some parts of the world.

Contact allergens

Benzyl penicillin is actually used only intravenously. It was formerly a frequent cause of contact allergy in health care workers. Facial contact dermatitis was recently reported in a nurse.

Pharmacokinetics

Oral absorption: 2–25% Cmax 0.6 g intramuscular: 12 mg/L 3 g intravenous (3–5 min): 400 mg/L Plasma half-life: 0.5 h Volume of distribution: 0.2–0.7 L/kg Plasma protein binding: 60% Absorption Benzylpenicillin is unstable in acid and destroyed in the stomach. As a result, plasma concentrations obtained after oral administration are variable, and are depressed by administration with food. It is absorbed from serous cavities, joints and the subarachnoid space. It is not absorbed following applications to the skin, which should be avoided because of the likelihood of sensitization. Distribution The drug is widely distributed in most tissues and body fluids. Highest levels are found in the kidney, with lower levels in the liver, skin and intestines. Low concentrations appear in saliva and in maternal milk. It does not enter uninflamed bone or the CSF. Its entry is limited by its low pKa (2.6), which results in its almost complete ionization and very low lipid–water partition coefficient at pH 7.4. When the meninges are inflamed, the concentrations obtained in CSF are around 5% of the plasma level. In uremia, accumulated organic acids may enter the CSF and compete for transport of penicillin, causing the concentration to reach convulsive levels. It diffuses into wound exudates and experimental transudates when the serum level is high, and enters glandular secretions and the fetal circulation, whence it is excreted in increased concentrations into the amniotic fluid. Metabolism and excretion About 40% is metabolized in the liver, mainly to penicilloic acid. After oral dosing, unabsorbed drug is largely degraded by colonic bacteria and little activity remains in the feces. Concentrations 2–4 times those of the plasma are found in bile, but 60–90% is excreted in the urine, largely in the first hour. Probenecid causes a doubling of the peak concentration and prolongation of the plasma half-life. Other drugs, including aspirin, sulfonamides and some non-steroidal anti-inflammatory drugs and diuretics, may prolong the half-life.

Clinical Use

Different sources of media describe the Clinical Use of 61-33-6 differently. You can refer to the following data:
1. Serious infections caused by streptococci (including Str. pneumoniae) other than meningitis caused by penicillin-resistant pneumococci Serious infections caused by susceptible strains of staphylococci Meningococcal septicemia and meningitis Gonococcal infections caused by susceptible strains Syphilis (including neurosyphilis) and other spirochetal infections Anthrax Actinomycosis Clostridial infections Diphtheria (adjunctive therapy to antitoxin and for prevention of carrier state) Infections with other susceptible organisms, including Listeria monocytogenes, Pasteurella multocida, Erysipelothrix insidiosa and Fusobacterium
2. For years, the most popular penicillin has been penicillin G,or benzylpenicillin. In fact, with the exception of patients allergicto it, penicillin G remains the agent of choice for thetreatment of more different kinds of bacterial infection thanany other antibiotic. It was first made available as the watersolublesalts of potassium, sodium, and calcium. These saltsof penicillin are inactivated by the gastric juice and are noteffective when administered orally unless antacids, such ascalcium carbonate, aluminum hydroxide, and magnesiumtrisilicate; or a strong buffer, such as sodium citrate, isadded. Also, because penicillin is absorbed poorly from the intestinal tract, oral doses must be very large, about fivetimes the amount necessary with parenteral administration.Only after the production of penicillin had increased enoughto make low-priced penicillin available did the oral dosageforms become popular. The water-soluble potassium andsodium salts are used orally and parenterally to achieve highplasma concentrations of penicillin G rapidly. The morewater-soluble potassium salt usually is preferred when largedoses are required. Situations in which hyperkalemia is adanger, however, as in renal failure, require use of thesodium salt; the potassium salt is preferred for patients onsalt-free diets or with congestive heart conditions.

Side effects

Benzylpenicillin has low toxicity, except for the nervous system (into which it does not normally penetrate), where it is one of the most active convulsants among the β-lactam agents. Excessively high intravenous doses may induce convulsions and intrathecal doses should never exceed 12 mg (20 000 units) in adults or 3 mg (5000 units) in a child as a single daily dose. Inadvertent intravascular administration, especially direct injection into arteries, can cause serious neurotoxic damage, including hyperreflexia, myoclonic twitches, seizures and coma. Massive intravenous doses of the sodium or potassium salts can lead to severe or fatal electrolyte disturbances. In patients treated with large doses of the potassium salt (60 g or more per day), hyponatremia, hyperkalemia and metabolic acidosis can develop. Thrombocytopenia and platelet dysfunction resulting in coagulopathy and involving several different mechanisms have been described. Neutropenia associated with fever and allergic rash appears to be related to total dose, usually in excess of 90 g. Although it can be very severe, in most patients recovery occurs within a few days of withdrawal of treatment. Large doses (24 g [40 megaunits] per day intravenously), or smaller doses given to patients with impaired renal function, may interfere with platelet function. The most dramatic untoward response is anaphylactic shock due to allergy . In addition to the generalized allergic reactions, particular organs may be damaged by a variety of immunological mechanisms. Hemolytic anemia occurs only in patients who have been treated previously with penicillin, and again receive a prolonged course of large doses (commonly 12 g per day). Reversible hemolysis is due to the action of anti-penicillin immunoglobulin G (IgG) on cells that have absorbed the antibiotic. Nephritis, resulting in dysuria, pyuria, proteinuria, azotemia and histological evidence of nephritis of allergic origin, is only rarely seen, usually in patients receiving large doses (12–36 g [20–60 megaunits] per day).

Safety Profile

Poison by ingestion, intravenous,intracerebral, intraspinal, subcutaneous, and possibly otherroutes. Human (child) systemic effects by parenteral route:changes in cochlear (inner ear) structure or function,convulsions, and dyspnea. Questionable carcin

Drug interactions

Potentially hazardous interactions with other drugs Reduced excretion of methotrexate.

Metabolism

Benzylpenicillin is metabolised to a limited extent and the penicilloic acid derivative has been recovered in the urine. Benzylpenicillin is rapidly excreted in the urine; about 20% of an oral dose appears unchanged in the urine; about 60-90% of an IM dose of benzylpenicillin undergoes renal elimination, 10% by glomerular filtration and 90% by tubular secretion, mainly within the first hour. Significant concentrations occur in bile, but in patients with normal renal function only small amounts are excreted via the bile. Renal tubular secretion is inhibited by probenecid, which can be given to increase plasma-penicillin concentrations and prolong half-life.

Check Digit Verification of cas no

The CAS Registry Mumber 61-33-6 includes 5 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 2 digits, 6 and 1 respectively; the second part has 2 digits, 3 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 61-33:
(4*6)+(3*1)+(2*3)+(1*3)=36
36 % 10 = 6
So 61-33-6 is a valid CAS Registry Number.
InChI:InChI=1/C16H18N2O4S/c1-16(2)12(15(21)22)18-13(20)11(14(18)23-16)17-10(19)8-9-6-4-3-5-7-9/h3-7,11-12,14H,8H2,1-2H3,(H,17,19)(H,21,22)/t11-,12?,14-/m1/s1

61-33-6SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 18, 2017

Revision Date: Aug 18, 2017

1.Identification

1.1 GHS Product identifier

Product name benzylpenicillin

1.2 Other means of identification

Product number -
Other names cilloral

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only. Veterinary Drug: ANTIMICROBIAL_AGENT
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:61-33-6 SDS

61-33-6Synthetic route

ampicillin
69-53-4

ampicillin

1-chlorocarbonyl-2-oxo-3-methylcarbonyl-imidazolidine
41730-71-6

1-chlorocarbonyl-2-oxo-3-methylcarbonyl-imidazolidine

sodium 2-ethylhexanoic acid

sodium 2-ethylhexanoic acid

penicillin G
61-33-6

penicillin G

Conditions
ConditionsYield
With triethylamine In methanol; aqueous tetrahydrofurane; water; ethyl acetate95%
With triethylamine In methanol; aqueous tetrahydrofurane; water; ethyl acetate95%
With triethylamine In methanol; aqueous tetrahydrofurane; water; ethyl acetate95%
phosgene
75-44-5

phosgene

5-amino-2-p-ethylanilino-4-hydroxy-pyrimidine

5-amino-2-p-ethylanilino-4-hydroxy-pyrimidine

amoxycillin trihydrate

amoxycillin trihydrate

A

D-α-[3-(2-p-ethylanilino-4-hydroxy-5-pyrimidyl)-ureido]-p-hydroxy-benzyl-penicillin-sodium

D-α-[3-(2-p-ethylanilino-4-hydroxy-5-pyrimidyl)-ureido]-p-hydroxy-benzyl-penicillin-sodium

B

penicillin G
61-33-6

penicillin G

Conditions
ConditionsYield
With triethylamineA 94%
B n/a
5-amino-2-ethoxycarbonyl-methylamino-4-hydroxy-pyrimidine

5-amino-2-ethoxycarbonyl-methylamino-4-hydroxy-pyrimidine

amoxycillin trihydrate

amoxycillin trihydrate

A

D-α-[3-(2-{ethoxycarbonylmethylamino}-4-hydroxy-5-pyrimidinyl)-ureido]-p-hydroxy-benzylpenicillin sodium

D-α-[3-(2-{ethoxycarbonylmethylamino}-4-hydroxy-5-pyrimidinyl)-ureido]-p-hydroxy-benzylpenicillin sodium

B

penicillin G
61-33-6

penicillin G

Conditions
ConditionsYield
With triethylamineA 88%
B n/a
phosgene
75-44-5

phosgene

5-Amino-2-(m-chlorobenzyl)-4-hydroxy-pyrimidine

5-Amino-2-(m-chlorobenzyl)-4-hydroxy-pyrimidine

amoxycillin trihydrate

amoxycillin trihydrate

A

D-α-[3-(2-m-chlorobenzy-4-hydroxy-5-pyrimidyl)-ureido]-p-hydroxybenzyl-penicillin sodium

D-α-[3-(2-m-chlorobenzy-4-hydroxy-5-pyrimidyl)-ureido]-p-hydroxybenzyl-penicillin sodium

B

penicillin G
61-33-6

penicillin G

Conditions
ConditionsYield
With triethylamineA 88%
B n/a
N-propionyl-N-methyl-carbamic acid chloride

N-propionyl-N-methyl-carbamic acid chloride

ampicillin
69-53-4

ampicillin

penicillin G
61-33-6

penicillin G

Conditions
ConditionsYield
With hydrogenchloride; triethylamine In tetrahydrofuran; aqueous tetrahydrofurane85%
phosgene
75-44-5

phosgene

5-amino-4-hydroxy-2-m,p-dimethoxyanilino-pyrimidine

5-amino-4-hydroxy-2-m,p-dimethoxyanilino-pyrimidine

amoxycillin trihydrate
24356-58-9, 61336-70-7

amoxycillin trihydrate

A

D-α-[3-(4-hydroxy-2-m,p-dimethoxyanilino-5-pyrimidyl)-ureido]-p-hydroxybenzyl-penicillin sodium

D-α-[3-(4-hydroxy-2-m,p-dimethoxyanilino-5-pyrimidyl)-ureido]-p-hydroxybenzyl-penicillin sodium

B

penicillin G
61-33-6

penicillin G

Conditions
ConditionsYield
With triethylamineA 81%
B n/a
5-Amino-4-hydroxy-(2'-ethoxycarbonyl-ethylamino)-pyrimidine
76592-26-2

5-Amino-4-hydroxy-(2'-ethoxycarbonyl-ethylamino)-pyrimidine

amoxycillin trihydrate

amoxycillin trihydrate

A

D-α-[3-(2-{2'-ethoxycarbonylethylamino}-4-hydroxy-5-pyrimidinyl)-ureido]-p-hydroxy-benzylpencillin sodium

D-α-[3-(2-{2'-ethoxycarbonylethylamino}-4-hydroxy-5-pyrimidinyl)-ureido]-p-hydroxy-benzylpencillin sodium

B

penicillin G
61-33-6

penicillin G

Conditions
ConditionsYield
With triethylamineA 80%
B n/a
5-amino-4-hydroxy-2-(3'-pyridylmethylamino)-pyrimidine

5-amino-4-hydroxy-2-(3'-pyridylmethylamino)-pyrimidine

amoxycillin trihydrate

amoxycillin trihydrate

A

D-α-{3-[4-Hydroxy-2-(3'-pyridylmethylamino)-5-pyrimidinyl]-ureido}-p-hydroxy-benzyl-penicillin sodium

D-α-{3-[4-Hydroxy-2-(3'-pyridylmethylamino)-5-pyrimidinyl]-ureido}-p-hydroxy-benzyl-penicillin sodium

B

penicillin G
61-33-6

penicillin G

Conditions
ConditionsYield
With triethylamineA 79%
B n/a
5-amino-2-m,m-dichloroanilino-4-hydroxy-pyrimidine

5-amino-2-m,m-dichloroanilino-4-hydroxy-pyrimidine

amoxycillin trihydrate
24356-58-9, 61336-70-7

amoxycillin trihydrate

A

D-α-[3-(2-m,m-dichloroanilino-4-hydroxy-5-pyrimidyl)-ureido]-p-hydroxybenzyl-penicillin sodium

D-α-[3-(2-m,m-dichloroanilino-4-hydroxy-5-pyrimidyl)-ureido]-p-hydroxybenzyl-penicillin sodium

B

penicillin G
61-33-6

penicillin G

Conditions
ConditionsYield
With triethylamineA 78.5%
B n/a
phosgene
75-44-5

phosgene

A

D-α-[3-(2-cyclopropyl-4-hydroxy-5-pyrimidyl)-ureido]-benzyl-penicillin sodium

D-α-[3-(2-cyclopropyl-4-hydroxy-5-pyrimidyl)-ureido]-benzyl-penicillin sodium

B

penicillin G
61-33-6

penicillin G

Conditions
ConditionsYield
With triethylamineA 78%
B n/a
phosgene
75-44-5

phosgene

5-amino-4-hydroxy-2-methylmercapto-pyrimidine

5-amino-4-hydroxy-2-methylmercapto-pyrimidine

amoxycillin trihydrate

amoxycillin trihydrate

A

D-α-[3-(4-hydroxy-2-methylmercapto-5-pyrimidyl)-ureido]-p-hydroxybenzyl-penicillin sodium

D-α-[3-(4-hydroxy-2-methylmercapto-5-pyrimidyl)-ureido]-p-hydroxybenzyl-penicillin sodium

B

penicillin G
61-33-6

penicillin G

Conditions
ConditionsYield
With triethylamineA 77%
B n/a
phosgene
75-44-5

phosgene

A

D-α-[3-(4-hydroxy-2-p-methoxyanilino-5-pyrimidyl)-ureido]-benzyl-penicillin-sodium

D-α-[3-(4-hydroxy-2-p-methoxyanilino-5-pyrimidyl)-ureido]-benzyl-penicillin-sodium

B

penicillin G
61-33-6

penicillin G

Conditions
ConditionsYield
With triethylamineA 77%
B n/a
phosgene
75-44-5

phosgene

5-amino-4-hydroxy-2-(2'-thienylmethylamino)-pyrimidine

5-amino-4-hydroxy-2-(2'-thienylmethylamino)-pyrimidine

amoxycillin trihydrate

amoxycillin trihydrate

A

D-α-{3-[4-Hydroxy-2-(2'-thienylmethylamino)-5-pyrimidinyl]-ureido}-p-hydroxy-benzyl-penicillin sodium

D-α-{3-[4-Hydroxy-2-(2'-thienylmethylamino)-5-pyrimidinyl]-ureido}-p-hydroxy-benzyl-penicillin sodium

B

penicillin G
61-33-6

penicillin G

Conditions
ConditionsYield
With triethylamineA 76%
B n/a
5-Amino-4-hydroxy-(2'-methylmercapto-ethylamino)-pyrimidine
76592-27-3

5-Amino-4-hydroxy-(2'-methylmercapto-ethylamino)-pyrimidine

amoxycillin trihydrate

amoxycillin trihydrate

A

D-α-[3-(4-hydroxy-2-{2'-methylmercaptoethylamino}-5-pyrimidinyl)-ureido]-p-hydroxy-benzylpenicillin sodium

D-α-[3-(4-hydroxy-2-{2'-methylmercaptoethylamino}-5-pyrimidinyl)-ureido]-p-hydroxy-benzylpenicillin sodium

B

penicillin G
61-33-6

penicillin G

Conditions
ConditionsYield
With triethylamineA 75%
B n/a
phosgene
75-44-5

phosgene

5-amino-2-m-chloroanilino-4-hydroxy-pyrimidine

5-amino-2-m-chloroanilino-4-hydroxy-pyrimidine

amoxycillin trihydrate

amoxycillin trihydrate

A

D-α-[3-(2-m-chloroanilino-4-hydroxy-5-pyrimidyl)-ureido]-p-hydroxybenzyl-penicillin-sodium

D-α-[3-(2-m-chloroanilino-4-hydroxy-5-pyrimidyl)-ureido]-p-hydroxybenzyl-penicillin-sodium

B

penicillin G
61-33-6

penicillin G

Conditions
ConditionsYield
A 75%
B n/a
penicillin G
61-33-6

penicillin G

Trimethylenediamine
109-76-2

Trimethylenediamine

C19H26N4O3S

C19H26N4O3S

Conditions
ConditionsYield
With 1-hydroxy-pyrrolidine-2,5-dione; dicyclohexyl-carbodiimide In dichloromethane at 0 - 20℃; for 3h; Inert atmosphere;100%
penicillin G
61-33-6

penicillin G

Penicillin G potassium
113-98-4

Penicillin G potassium

Conditions
ConditionsYield
With potassium carbonate In acetic acid butyl ester; water; butan-1-ol at 45 - 48℃; Product distribution / selectivity;94.5%
With potassium carbonate In acetic acid butyl ester; water; butan-1-ol at 50 - 60℃; Product distribution / selectivity;91%
penicillin G
61-33-6

penicillin G

7-Aminocephalosporanic acid t-butyl ester
6187-87-7

7-Aminocephalosporanic acid t-butyl ester

7-(6-phenylacetamidopenicillanamido)cephalosporanic acid t-butyl ester

7-(6-phenylacetamidopenicillanamido)cephalosporanic acid t-butyl ester

Conditions
ConditionsYield
With dicyclohexyl-carbodiimide In ethyl acetate for 24h; Ambient temperature;89.5%
penicillin G
61-33-6

penicillin G

A

(5S,6S,3S)-benzyl-D-penicilloic acid
89014-19-7

(5S,6S,3S)-benzyl-D-penicilloic acid

B

(5R,6S,3S)-benzyl-D-penicilloic acid
87492-68-0

(5R,6S,3S)-benzyl-D-penicilloic acid

Conditions
ConditionsYield
With Zn(II) cyclen; water at 15 - 35℃; Rate constant; Kinetics; Thermodynamic data;A 88%
B 12%
With Zn(II) cyclen-OH-; water at 15 - 35℃; Rate constant; Kinetics; Thermodynamic data;A 88%
B 12%
penicillin G
61-33-6

penicillin G

[(chlorosulfonyl)oxy]methyl sulfurochloridate
92975-18-3

[(chlorosulfonyl)oxy]methyl sulfurochloridate

bis-(6β-phenylacetamido-penicillanoyloxy)-methane
35131-81-8

bis-(6β-phenylacetamido-penicillanoyloxy)-methane

Conditions
ConditionsYield
With tetra(n-butyl)ammonium hydrogensulfate; sodium hydrogencarbonate In dichloromethane 1.) 20-22 deg C, 2.) 30 min;80%

61-33-6Relevant articles and documents

Light-triggered hydrophilic drug release from liposomes through removal of a photolabile protecting group

Goto, Yuya,Ueda, Masafumi,Sugikawa, Kouta,Yasuhara, Kazuma,Ikeda, Atsushi

, p. 166 - 171 (2019)

The antibiotic penicillin G cannot be completely incorporated into hydrophobic lipid-membranes owing to its hydrophilicity. Through modification with a hydrophobic and photolabile protecting group, penicillin G was effectively incorporated into liposomes and released by photoirradiation at 365?nm.

-

Sheehan,J.C.,Daves,G.D.

, p. 2006 - 2008 (1964)

-

α-Carboxy-6-nitroveratryl: A photolabile protecting group for carboxylic acids

Russell, Alexander G.,Ragoussi, Maria-Eleni,Ramalho, Rui,Wharton, Christopher W.,Carteau, David,Bassani, Dario M.,Snaith, John S.

supporting information; scheme or table, p. 4648 - 4651 (2010/09/14)

(Figure presented) The synthesis of a new photolabile protecting group for carboxylic acids, α-carboxy-6-nitroveratryl (αCNV), is described. Bromide 3, prepared in four steps from 3,4-dimethoxyphenylacetic acid, was used to alkylate carboxylic acids under mild conditions in good yield. Palladium-catalyzed deallylation afforded the acids 4a-h, which underwent rapid and quantitative photolysis at wavelengths longer than 300 nm to liberate the carboxylic acid in good to quantitative yield. The rate of photolysis and quantum yield were determined to be 325 s-1 and 0.17.

Prop-2-ynyl as a protective group for carboxylic acids: A mild method for the highly selective deprotection of prop-2-ynyl esters using tetrathiomolybdate

Ilankumaran, Palanichamy,Manoj,Chandrasekaran, Srinivasan

, p. 1957 - 1958 (2007/10/03)

It is shown that prop-2-ynyl esters are useful protecting groups for carboxylic acids and that they are selectively deprotected in the presence of other esters on treatment with tetrathiomolybdate under mild conditions.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 61-33-6